To assess the remission rate of daratumumab, carfilzomib, and dexamethasone (DKd) in patients with high-risk (HR) smoldering multiple myeloma (SMM) by determining the minimal residual disease (MRD) negative complete response (CR) rate by up to 12 cycles of induction therapy using flow cytometry.
SparkCures ID | 1183 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 11 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
EXCLUSION CRITERIA:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers